Full Press Release Details
Pharma Reports Positive Top-Line Results from Phase III Trial of EM-100 Ophthalmic Solution
PARK, Ill., July 24, 2018 -- Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, announced positive top-line results
for its phase III study of EM-100 ophthalmic solution. If approved, EM-100 would be the first topical, preservative-free
formulation for the treatment of ocular itching associated with allergic conjunctivitis. Results from the trial demonstrated non-inferiority
of EM-100 topical ophthalmic solution to the comparator product in the treatment of ocular itching. Furthermore, the product demonstrated
statistically significant superiority to placebo at all time points measured with no adverse events.
believes the availability of a preservative-free product for this indication would offer patients a valuable new treatment option.
"We look forward to a timely FDA review and bringing the product to patients in 2019," said Sean Brynjelsen, chief
executive officer of Eton Pharma. According to IQVIA, the U.S. market for anti-allergy ophthalmic products is currently more than
Pharmaceuticals, Inc., a privately-held company, is a specialty pharmaceutical company focused on developing and commercializing
innovative products utilizing the FDA's 505(b)(2) regulatory pathway. Eton has two products filed with the FDA and
six additional product candidates under development across various liquid dosage forms, including injectables, oral liquids, and